High Grade Glioma Drug Profiles and Clinical Trials - Global Trends and Analysis Review, H1 2018 - ResearchAndMarkets.com

DUBLIN--()--The "High Grade Glioma Drug Profiles and Clinical Trials- Global Trends and Analysis Review, H1 2018" report has been added to ResearchAndMarkets.com's offering.

This Glioma clinical trials report provides comprehensive analysis and trends in global Glioma disease clinical trials. The research work analyzes the evolution of Glioma clinical trial trends across countries and regions.

The report focuses on the drugs and therapies being evaluated for Glioma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner offering quick access to Glioma clinical trials.

Major drugs under development in Glioma are provided in the report, along with details of mechanism of action, route of administration, target, therapy, molecule and class.

Key Topics Covered:

1 Table of Contents

2 Executive Summary

3 High Grade Glioma Drugs in Ongoing and Completed Trials

4 Global High Grade Glioma Clinical Trial Research Trends

5 Europe High Grade Glioma Clinical Trial Research Trends

6 Eastern Mediterranean High Grade Glioma Clinical Trial Research Trends

7 North America High Grade Glioma Clinical Trial Research Trends

8 South East Asia High Grade Glioma Clinical Trial Research Trends

9 Western Pacific High Grade Glioma Clinical Trial Research Trends

10 Recent Clinical Trials- Snapshots

11 Appendix

For more information about this report visit https://www.researchandmarkets.com/research/bwcwbs/high_grade_glioma?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs , Clinical Trials

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Brain Cancer Drugs , Clinical Trials